Zoetis Inc. (NYSE:ZTS) Shares Acquired by Hantz Financial Services Inc.

Hantz Financial Services Inc. increased its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 15.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 162,656 shares of the company's stock after acquiring an additional 21,357 shares during the period. Hantz Financial Services Inc.'s holdings in Zoetis were worth $26,502,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ZTS. AQR Capital Management LLC lifted its position in shares of Zoetis by 14.1% in the 2nd quarter. AQR Capital Management LLC now owns 97,480 shares of the company's stock worth $16,899,000 after purchasing an additional 12,063 shares during the period. Algert Global LLC grew its holdings in Zoetis by 29.5% during the second quarter. Algert Global LLC now owns 1,924 shares of the company's stock worth $334,000 after buying an additional 438 shares in the last quarter. Creative Planning lifted its position in shares of Zoetis by 37.5% during the second quarter. Creative Planning now owns 83,231 shares of the company's stock valued at $14,429,000 after purchasing an additional 22,683 shares in the last quarter. NewEdge Advisors LLC boosted its stake in shares of Zoetis by 32.8% in the 2nd quarter. NewEdge Advisors LLC now owns 35,192 shares of the company's stock worth $6,101,000 after buying an additional 8,688 shares during the last quarter. Finally, Quarry LP grew its stake in Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company's stock valued at $36,000 after purchasing an additional 153 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on ZTS shares. Stifel Nicolaus dropped their price objective on Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. UBS Group started coverage on shares of Zoetis in a report on Monday, December 9th. They issued a "neutral" rating and a $196.00 price target for the company. JPMorgan Chase & Co. boosted their price objective on Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a report on Friday, October 11th. Leerink Partners started coverage on Zoetis in a research note on Monday, December 2nd. They set an "outperform" rating and a $215.00 price target for the company. Finally, Morgan Stanley decreased their target price on shares of Zoetis from $248.00 to $243.00 and set an "overweight" rating on the stock in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Zoetis presently has a consensus rating of "Buy" and an average target price of $215.00.

Zoetis Price Performance

Zoetis stock traded down $0.09 during mid-day trading on Wednesday, hitting $170.33. The stock had a trading volume of 2,111,837 shares, compared to its average volume of 2,740,963. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The firm has a market capitalization of $76.85 billion, a P/E ratio of 32.02, a P/E/G ratio of 2.57 and a beta of 0.89. The firm's 50 day moving average is $169.93 and its 200 day moving average is $179.65.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion during the quarter, compared to analysts' expectations of $2.29 billion. During the same quarter last year, the business posted $1.36 earnings per share. The firm's revenue was up 11.6% on a year-over-year basis. On average, sell-side analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, January 21st. This is an increase from Zoetis's previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.17%. Zoetis's payout ratio is 37.59%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.